These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in reducing blood glucose levels. https://aadamlhdm949297.widblog.com/93895825/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide